- Watch The JD Rucker Show every day to be truly informed.
President-elect Donald Trump has refuted a Washington Post report suggesting his aides were considering a more restrained tariff policy. The report claimed that Trump’s transition team was contemplating a tariff plan that would be less extensive than his campaign promises, targeting only imports deemed critical to national or economic security.
Trump took to his Truth Social platform to dismiss these claims as “Fake News.” He stated, “The story in the Washington Post, quoting so-called anonymous sources, which don’t exist, incorrectly states that my tariff policy will be pared back. That is wrong. The Washington Post knows it’s wrong. It’s just another example of Fake News.”
During his campaign, Trump had proposed imposing tariffs of 10% or 20% across the board on all imported goods, with a 60% tariff specifically on Chinese imports. However, the Washington Post’s article suggested a shift towards a more targeted approach, focusing on sectors like the defense industrial supply chain, critical medical supplies, and energy production.
The Washington Post’s report, which cited three anonymous sources, indicated that these plans were still in flux. It also noted that the Trump administration had recently considered tariffs on all electric battery materials globally to encourage domestic production, as reported by Reuters.
Despite this, Trump’s denial has led to increased uncertainty among business leaders regarding future U.S. trade policies. Financial markets reacted positively to the report, with some investors hoping for a less aggressive tariff stance, which could lead to reduced inflationary pressures.
Trump’s firm rebuttal underscores his intention to maintain the tariff policies he outlined during his campaign, although the exact implementation remains to be seen as he prepares to take office.
Article generated from legacy media reports.
YouTube Mirror:
What Would You Do If Pharmacies Couldn’t Provide You With Crucial Medications or Antibiotics?
The medication supply chain from China and India is more fragile than ever since Covid. The US is not equipped to handle our pharmaceutical needs. We’ve already seen shortages with antibiotics and other medications in recent months and pharmaceutical challenges are becoming more frequent today.
Our partners at Jase Medical offer a simple solution for Americans to be prepared in case things go south. Their “Jase Case” gives Americans emergency antibiotics they can store away while their “Jase Daily” offers a wide array of prescription drugs to treat the ailments most common to Americans.
They do this through a process that embraces medical freedom. Their secure online form allows board-certified physicians to prescribe the needed drugs. They are then delivered directly to the customer from their pharmacy network. The physicians are available to answer treatment related questions.
